Najafzadeh, Mehdi http://orcid.org/0000-0003-4503-1057
Schneeweiss, Sebastian
Choudhry, Niteesh K.
Avorn, Jerry
Gagne, Joshua J.
Article History
First Online: 21 September 2018
Compliance with Ethical Standards
:
: No sources of funding were received for the preparation of this article.
: Sebastian Schneeweiss is the principal investigator of the Harvard-Brigham Drug Safety and Risk Management Research Center funded by the US Food and Drug Administration (FDA). His work is partially funded by grants/contracts from Patient Centered Outcome Research Institute; the FDA; and the National Heart, Lung, and Blood Institute. Sebastian Schneeweiss is also a consultant to WHISCON, LLC and to Aetion, Inc., a software manufacturer of which he also owns shares. He is the principal investigator of investigator-initiated grants to Brigham and Women’s Hospital from Novartis, and Boehringer Ingelheim unrelated to the topic of this study. Mehdi Najafzadeh is the principal investigator of an investigator-initiated unrestricted grant from Novartis Pharmaceuticals Corporation and Baxalta to Brigham and Women’s Hospital unrelated to the topic of this study. Joshua J. Gagne is the principal investigator of an investigator-initiated unrestricted grant from Novartis Pharmaceuticals Corporation to Brigham and Women’s Hospital. He is a consultant to Aetion, Inc., a software company. Niteesh K. Choudhry, Jerry Avorn, and Joshua J. Gagne have no conflicts of interest directly relevant to the content of this article.